This company has been marked as potentially delisted and may not be actively trading. Presbia (LENS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LENS vs. NVCR, UFPT, ATRC, ATEC, IART, PLSE, FNA, TNDM, MDXG, and AORTShould you be buying Presbia stock or one of its competitors? The main competitors of Presbia include NovoCure (NVCR), UFP Technologies (UFPT), AtriCure (ATRC), Alphatec (ATEC), Integra LifeSciences (IART), Pulse Biosciences (PLSE), Paragon 28 (FNA), Tandem Diabetes Care (TNDM), MiMedx Group (MDXG), and Artivion (AORT). Presbia vs. NovoCure UFP Technologies AtriCure Alphatec Integra LifeSciences Pulse Biosciences Paragon 28 Tandem Diabetes Care MiMedx Group Artivion NovoCure (NASDAQ:NVCR) and Presbia (NASDAQ:LENS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Do analysts rate NVCR or LENS? NovoCure currently has a consensus target price of $32.83, suggesting a potential upside of 77.48%. Given NovoCure's stronger consensus rating and higher possible upside, research analysts clearly believe NovoCure is more favorable than Presbia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Presbia 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation and earnings, NVCR or LENS? Presbia has lower revenue, but higher earnings than NovoCure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovoCure$605.22M3.41-$207.04M-$1.56-11.86Presbia$20K22,751.27-$8.41MN/AN/A Does the media favor NVCR or LENS? In the previous week, NovoCure had 30 more articles in the media than Presbia. MarketBeat recorded 30 mentions for NovoCure and 0 mentions for Presbia. NovoCure's average media sentiment score of 0.32 beat Presbia's score of 0.00 indicating that NovoCure is being referred to more favorably in the media. Company Overall Sentiment NovoCure Neutral Presbia Neutral Is NVCR or LENS more profitable? NovoCure has a net margin of -25.93% compared to Presbia's net margin of -36,604.35%. NovoCure's return on equity of -41.48% beat Presbia's return on equity.Company Net Margins Return on Equity Return on Assets NovoCure-25.93% -41.48% -12.74% Presbia -36,604.35%-414.02%-195.56% Which has more risk and volatility, NVCR or LENS? NovoCure has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Presbia has a beta of 2.57, indicating that its stock price is 157% more volatile than the S&P 500. Do institutionals and insiders believe in NVCR or LENS? 84.6% of NovoCure shares are held by institutional investors. Comparatively, 16.4% of Presbia shares are held by institutional investors. 6.3% of NovoCure shares are held by insiders. Comparatively, 74.2% of Presbia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer NVCR or LENS? NovoCure received 322 more outperform votes than Presbia when rated by MarketBeat users. However, 68.42% of users gave Presbia an outperform vote while only 62.98% of users gave NovoCure an outperform vote. CompanyUnderperformOutperformNovoCureOutperform Votes47862.98% Underperform Votes28137.02% PresbiaOutperform Votes15668.42% Underperform Votes7231.58% SummaryNovoCure beats Presbia on 11 of the 16 factors compared between the two stocks. Get Presbia News Delivered to You Automatically Sign up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENS vs. The Competition Export to ExcelMetricPresbiaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$455.03M$4.29B$5.44B$7.80BDividend YieldN/A46.47%5.43%4.30%P/E RatioN/A30.2922.1418.40Price / Sales22,751.2752.52389.70101.29Price / CashN/A51.0838.2034.62Price / Book293.436.096.664.18Net Income-$8.41M$67.60M$3.21B$247.71M Presbia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENSPresbiaN/A$26.41-0.8%N/AN/A$455.03M$20,000.000.0024NVCRNovoCure3.2469 of 5 stars$15.58flat$34.17+119.3%+51.3%$1.71B$605.22M-11.131,320Earnings ReportAnalyst ForecastNews CoverageGap UpUFPTUFP Technologies2.0333 of 5 stars$210.63-0.2%$392.00+86.1%-1.4%$1.62B$504.42M30.052,020Upcoming EarningsNews CoveragePositive NewsATRCAtriCure4.0742 of 5 stars$31.74-0.8%$49.44+55.8%+47.7%$1.56B$465.31M-33.411,050Upcoming EarningsNews CoveragePositive NewsATECAlphatec4.0954 of 5 stars$10.64+0.8%$17.67+66.0%-6.0%$1.53B$611.56M-8.31700Upcoming EarningsPositive NewsIARTIntegra LifeSciences4.3745 of 5 stars$15.19-4.0%$22.71+49.5%-40.8%$1.17B$1.61B-168.763,720PLSEPulse Biosciences1.0009 of 5 stars$17.29-2.5%N/A+167.7%$1.16B$700,000.000.00140News CoveragePositive NewsFNAParagon 281.5942 of 5 stars$13.11+0.1%$14.20+8.4%+46.1%$1.10B$256.18M-17.71343,000High Trading VolumeTNDMTandem Diabetes Care4.2926 of 5 stars$16.39-2.8%$43.88+167.7%-49.2%$1.09B$940.20M-8.492,600Upcoming EarningsNews CoveragePositive NewsMDXGMiMedx Group3.1886 of 5 stars$6.55-1.9%$12.00+83.2%+10.6%$965.25M$348.88M11.91870Upcoming EarningsAORTArtivion2.9988 of 5 stars$22.60-1.4%$31.40+38.9%+17.5%$964.77M$388.54M-1,130.001,300News Coverage Related Companies and Tools Related Companies NVCR Competitors UFPT Competitors ATRC Competitors ATEC Competitors IART Competitors PLSE Competitors FNA Competitors TNDM Competitors MDXG Competitors AORT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENS) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Presbia PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Presbia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LENS Stock Free LENS Stock Alerts